

RELEVANT EVENT

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley del Mercado de Valores*) Grifols, S.A. ("**Grifols**") hereby informs that it has received the approval of the United States' Food and Drug Administration ("**FDA**") for its new state-of-the-art fractionation facility in Clayton, (NC, United States) where production capacity of plasma will almost double to approximately 6 million liters annually.

Grifols' products are used to treat rare and chronic diseases such as a neurological disorder, immune deficiencies, hemophilia and genetic emphysema. The plant will be operational in 2015 as planned.

With this approval by the FDA, Grifols increases its global fractionation capacity above 12 million liters of plasma per year.

More than \$370 million have been invested in the new plant in Clayton since its inception in 2010, it has an area of 14,400 m² and it will employ over 200 people.

This plant is one of the most technologically advanced fractionation facilities in the world.

Barcelona, on 17 November 2014

Raimon Grifols Roura
Secretary to the Board of Directors